Method for inducing extended self-renewal of functionally differentiated somatic cells
AssigneesInstitut National De La Sante Et De La Recherche Medicale (Inserm), Centre National de la Recherche Scientifique (CNRS), Universite De La Mediterranee Aix-Marseille II
InventorMichael Sieweke
Life of this patent
Estimating the term…
Abstract
Mouse or human hematopoietic cells are transduced in vitro with one or more vectors encoding c-Myc and Klf4 genes, to overexpress both c-Myc and Klf4. The transduced cells produce self-renewing populations of macrophages, monocytes, monocyte-derived macrophages, B lymphocytes or erythroid cells. The self-renewing cell populations may include a pharmaceutical composition.
Claims8
A method for inducing extended self-renewal of mouse or human macrophages, B lymphocytes or erythroid cells comprising a step of activating overexpression of a c-Myc gene and a Klf4 gene in said cells by transducing said cells in vitro with a retroviral vector encoding c-Myc and said Klf4 gene.
A population of mouse or human macrophages, B lymphocytes or erythroid cells in which extended self-renewal has been induced by an in vitro method comprising a step of activating overexpression of a c-Myc gene and a Klf4 gene in said cells by transducing said cells with a retroviral vector encoding said c-Myc gene and said Klf4 gene.
A pharmaceutical composition comprising a population of mouse or human macrophages, B lymphocytes or erythroid cells in which extended self-renewal has been induced by an in vitro method comprising a step of activating overexpression of a c-Myc gene and a Klf4 gene in said cells by transducing said cells with a retroviral vector encoding said c-Myc gene and said Klf4 gene;
- and a pharmaceutically acceptable carrier or excipient.
A method for inducing extended self-renewal of mouse or human macrophages comprising a step of activating overexpression of a c-Myc gene and a Klf2 gene in said cells by transducing said cells in vitro with a retroviral vector encoding c-Myc and said Klf2 gene.
A population of mouse or human macrophages in which extended self-renewal has been induced by an in vitro method comprising a step of activating overexpression of a c-Myc gene and a Klf2 gene in said cells by transducing said cells with a retroviral vector encoding said c-Myc gene and said Klf2 gene.
A pharmaceutical composition comprising a population of mouse or human macrophages in which extended self-renewal has been induced by an in vitro method comprising a step of activating overexpression of a c-Myc gene and a Klf2 gene in said cells by transducing said cells with a retroviral vector encoding said c-Myc gene and said Klf2 gene;
- and a pharmaceutically acceptable carrier or excipient.
Dependencies are inferred from the claim text.